Clinical Trials Browser

Phase 2 × zimberelimab × 30 days × Clear all

NCT04791839 2026-05-06

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung